PEGOZAFERMIN DEMONSTRATED ROBUST HISTOLOGICAL IMPROVEMENT AND BENEFIT IN HEPATIC AND METABOLIC BIOMARKERS: RESULTS FROM A 48-WEEK MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2B TRIAL (ENLIVEN)

pegozafermin (BIO89-100) - 89Bio

J. Schattenberg1; A.J. Sanyal2; N. Alkhouri3; M.D. Gottwald4; S. Feng4; G.D. Agollah4; C.L. Hartsfield4; H. Mansbach4; M. Margalit5; R. Loomba6

Jul 9, 2025